A new weapon to boost cancer immunotherapy

The 4SC team monitors the expression of relevant genes in the tumours of patients before and after administration of domatinostat.

In recent years, immunooncology has paved new avenues for effective treatment across cancer types. In addition to cytotoxic chemotherapy, we can now harness the power of the human immune response against malignant cells. However, immunotherapy is not perfect, and as always, cancer has mechanisms to evade these attacks. Dr Svetlana Hamm, Head of Research and Translational Medicine at 4SC in […]

Read More… from A new weapon to boost cancer immunotherapy